EuReCa-M Working Group

How renal dysfunction engenders cardiovascular complications is still poorly understood. Notwithstanding interest in CKD is on the rise in the medical community at large, renal dysfunction remains undervalued in clinical research.

Despite notable exceptions, by now there are still few concrete signs that cardiovascular trialists take into proper consideration patients with CKD in the design of their studies. Indeed, history is one of deliberate (but incomplete) exclusion. Although the number of observational and mechanistic studies at the kidney-heart interface is now conspicuous, specifically designed research focusing on patients with both chronic kidney disease and the cardiovascular disease appears to be a priority issue, on both clinical and scientific grounds.

To fill in the gap, the aim and scope of EuReCa-M are to promote collaborations among European centres pursuing research in the overlapping area of cardiovascular and renal medicine.